Zacks Industry Outlook Spotlights Boston Scientific, Insulet, BioLife Solutions, and Allurion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 18 2025
0mins
Should l Buy BSX?
Source: NASDAQ.COM
Industry Challenges: The medical products industry is facing significant challenges, including cost inflation from tariffs, supply-chain delays, and regulatory uncertainties, which are impacting margins and growth outlooks.
Resilience Through Innovation: Companies like Boston Scientific, Insulet, BioLife Solutions, and Allurion Technologies are navigating these challenges by focusing on innovation, operational efficiencies, and strategic acquisitions to drive organic growth.
Emerging Trends: Key trends shaping the industry include the integration of AI and digital health, a shift towards ambulatory and home-based care, advancements in robotics and specialty therapeutics, and evolving regulatory frameworks that emphasize value-based care.
Market Performance: The medical products industry has underperformed compared to the broader market, with a decline of 1.8% over the past year, while companies are still positioned for potential growth through strategic investments and improved operational practices.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 61.280
Low
94.00
Averages
108.14
High
132.00
Current: 61.280
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ENCORE: UNDERWRITERS FOR IPO INCLUDE ROTHSCHILD & CO, STIFEL, WILLIAM BLAIR, WOLFE, NOMURA ALLIANCE, LIONTREE, THE RAINE GROUP, AND BLACKSTONE CAPITAL MARKETS
- Underwriters for IPO: Rothschild & Co, Stifel, William Blair, Wolfe, Nomura, Alliance, LionTree, The Raine Group, and Blackstone Capital Markets are the underwriters for the upcoming IPO.
- Company Focus: The IPO is likely to attract attention due to the involvement of prominent financial institutions and investment firms.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice Issued: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE: BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm for potential lead plaintiff appointment, indicating legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management provided overly positive statements while concealing the unsustainable growth rate of its U.S. EP segment, leading investors to misjudge the company's future performance and impacting market confidence.
- Disappointing Performance Impact: On February 4, 2026, Boston Scientific reported disappointing U.S. EP sales, resulting in a net income miss and a stock price drop of approximately 17.6% in one day, from $91.62 to $75.50, reflecting market disappointment in the company's outlook.
- Legal Action Deadline: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, with failure to register potentially resulting in lost claims, highlighting the legal pressures and potential financial losses facing the company.
See More
Investors Encouraged to Claim Against Boston Scientific
- Claim Opportunity: Faruq & Faruqi LLP is investigating potential claims against Boston Scientific Corporation, specifically for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, reminding them of their rights to participate in a class action lawsuit.
- Legal Consultation: Investors are encouraged to contact Faruq & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options for claims, ensuring timely action is taken.
- Lawsuit Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action is May 4, 2026, emphasizing the importance of prompt action to protect their interests.
- Law Firm Background: Faruq & Faruqi LLP is a leading national securities law firm focused on providing legal support to investors seeking compensation in securities litigation, highlighting its expertise in investor rights protection.
See More
Boston Scientific Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong reputation in the field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Brandon Walker Urges Boston Scientific Investors to Reach Out
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if the board breached fiduciary duties to shareholders, particularly following a class action complaint filed on March 5, 2026.
- False Statements Allegations: The lawsuit alleges that Boston Scientific failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the class period from July 23, 2025, to February 3, 2026, misleading investors and impacting the company's market performance.
- Increased Market Competition: Boston Scientific is facing new entrants in the market, which not only diminishes its share in the U.S. electrophysiology sector but also limits the company's growth potential, raising further concerns among investors.
- Shareholder Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them to understand their legal rights and potential claims, ensuring that shareholder interests are adequately protected.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific faces a class action for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, leading to misleading investor perceptions about its future prospects, with a lead plaintiff deadline of May 4, 2026, potentially undermining shareholder confidence.
- Eos Energy Lawsuit: Eos Energy is accused in a class action of failing to achieve necessary production ramp-up and experiencing excessive battery line downtime beyond industry norms, with a lead plaintiff deadline of May 5, 2026, which could negatively impact its market share.
- Soleno Therapeutics Lawsuit: Soleno is facing a class action for concealing safety issues in its DCCR clinical trial, with a lead plaintiff deadline of May 5, 2026, which may raise concerns about the commercial viability of its product.
- Nektar Therapeutics Lawsuit: Nektar is being sued for not adhering to applicable standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, which could affect the trial's results and the company's reputation.
See More
ENCORE: UNDERWRITERS FOR IPO INCLUDE ROTHSCHILD & CO, STIFEL, WILLIAM BLAIR, WOLFE, NOMURA ALLIANCE, LIONTREE, THE RAINE GROUP, AND BLACKSTONE CAPITAL MARKETS
- Underwriters for IPO: Rothschild & Co, Stifel, William Blair, Wolfe, Nomura, Alliance, LionTree, The Raine Group, and Blackstone Capital Markets are the underwriters for the upcoming IPO.
- Company Focus: The IPO is likely to attract attention due to the involvement of prominent financial institutions and investment firms.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice Issued: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE: BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm for potential lead plaintiff appointment, indicating legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management provided overly positive statements while concealing the unsustainable growth rate of its U.S. EP segment, leading investors to misjudge the company's future performance and impacting market confidence.
- Disappointing Performance Impact: On February 4, 2026, Boston Scientific reported disappointing U.S. EP sales, resulting in a net income miss and a stock price drop of approximately 17.6% in one day, from $91.62 to $75.50, reflecting market disappointment in the company's outlook.
- Legal Action Deadline: Shareholders must register by May 4, 2026, to participate in the class action lawsuit, with failure to register potentially resulting in lost claims, highlighting the legal pressures and potential financial losses facing the company.
See More
Investors Encouraged to Claim Against Boston Scientific
- Claim Opportunity: Faruq & Faruqi LLP is investigating potential claims against Boston Scientific Corporation, specifically for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, reminding them of their rights to participate in a class action lawsuit.
- Legal Consultation: Investors are encouraged to contact Faruq & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal rights and options for claims, ensuring timely action is taken.
- Lawsuit Deadline: Investors should be aware that the deadline to seek the role of lead plaintiff in the federal securities class action is May 4, 2026, emphasizing the importance of prompt action to protect their interests.
- Law Firm Background: Faruq & Faruqi LLP is a leading national securities law firm focused on providing legal support to investors seeking compensation in securities litigation, highlighting its expertise in investor rights protection.
See More
Boston Scientific Class Action Notice Issued
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first by ISS Securities Class Action Services in 2017, demonstrating its strong reputation in the field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Brandon Walker Urges Boston Scientific Investors to Reach Out
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if the board breached fiduciary duties to shareholders, particularly following a class action complaint filed on March 5, 2026.
- False Statements Allegations: The lawsuit alleges that Boston Scientific failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable during the class period from July 23, 2025, to February 3, 2026, misleading investors and impacting the company's market performance.
- Increased Market Competition: Boston Scientific is facing new entrants in the market, which not only diminishes its share in the U.S. electrophysiology sector but also limits the company's growth potential, raising further concerns among investors.
- Shareholder Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them to understand their legal rights and potential claims, ensuring that shareholder interests are adequately protected.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific faces a class action for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, leading to misleading investor perceptions about its future prospects, with a lead plaintiff deadline of May 4, 2026, potentially undermining shareholder confidence.
- Eos Energy Lawsuit: Eos Energy is accused in a class action of failing to achieve necessary production ramp-up and experiencing excessive battery line downtime beyond industry norms, with a lead plaintiff deadline of May 5, 2026, which could negatively impact its market share.
- Soleno Therapeutics Lawsuit: Soleno is facing a class action for concealing safety issues in its DCCR clinical trial, with a lead plaintiff deadline of May 5, 2026, which may raise concerns about the commercial viability of its product.
- Nektar Therapeutics Lawsuit: Nektar is being sued for not adhering to applicable standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, which could affect the trial's results and the company's reputation.
See More
